Skip to main content
NASDAQ:ICAD

iCAD Stock Forecast, Price & News

$15.39
+0.05 (+0.33 %)
(As of 05/17/2021 12:00 AM ET)
Add
Compare
Today's Range
$15.00
$15.92
50-Day Range
$14.90
$21.22
52-Week Range
$8.32
$21.44
Volume61,108 shs
Average Volume190,657 shs
Market Capitalization$384.49 million
P/E RatioN/A
Dividend YieldN/A
Beta1.3
30 days | 90 days | 365 days | Advanced Chart
Receive ICAD News and Ratings via Email

Sign-up to receive the latest news and ratings for iCAD and its competitors with MarketBeat's FREE daily newsletter.


iCAD logo

About iCAD

iCAD, Inc. provides image analysis, workflow solutions, and radiation therapy for the treatment of cancer in the United States. It operates through two segments, Cancer Detection and Cancer Therapy. The company offers PowerLook platform, which hosts the AI algorithm solutions and manages the communications between imaging acquisition systems, and image storage and review systems; SecondLook, a machine learning-based cancer detection algorithm that analyzes 2D full-field digital mammography images to identify and mark suspicious masses and calcifications; and automated density assessment solutions, which provides automated, consistent, and standardized density assessment. It also offers ProFound AI, a deep-learning algorithm designed to detect malignant soft-tissue densities and calcifications in digital breast tomosynthesis; ProFound AI Risk, a tool that provides breast cancer risk estimation based on a screening mammogram; and magnetic resonance imaging applications, a tool to detect breast and prostate cancer. In addition, the company offers VeraLook, a solution designed to support the detection of colonic polyps in conjunction with CT Colonography. Further, it provides Xoft Axxent electronic brachytherapy systems for the treatment of early stage breast, non-melanoma skin, and gynecological cancers to university research and community hospitals, cancer care clinics, veterinary facilities, and dermatology offices. The company serves healthcare centers through direct sales organizations, as well as through various original equipment manufacturer partners, distributors, and resellers. It also exports its products in Europe, Taiwan, Canada, China, and internationally. The company was formerly known as Howtek, Inc. and changed its name to iCAD, Inc. in June 2002. iCAD, Inc. was incorporated in 1984 and is headquartered in Nashua, New Hampshire.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
Current SymbolNASDAQ:ICAD
CUSIPN/A
Phone603-882-5200
Employees113
Year FoundedN/A

Sales & Book Value

Annual Sales$31.34 million
Book Value$0.26 per share

Profitability

Net Income$-13,550,000.00

Debt

Price-To-Earnings

Miscellaneous

Market Cap$384.49 million
Next Earnings Date8/3/2021 (Estimated)
OptionableOptionable

MarketRank

Overall MarketRank

1.71 out of 5 stars

Computer And Technology Sector

238th out of 1,551 stocks

Surgical & Medical Instruments Industry

28th out of 169 stocks

Analyst Opinion: 4.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











iCAD (NASDAQ:ICAD) Frequently Asked Questions

Is iCAD a buy right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for iCAD in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" iCAD stock.
View analyst ratings for iCAD
or view top-rated stocks.

What stocks does MarketBeat like better than iCAD?

Wall Street analysts have given iCAD a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but iCAD wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is iCAD's next earnings date?

iCAD is scheduled to release its next quarterly earnings announcement on Tuesday, August 3rd 2021.
View our earnings forecast for iCAD
.

How were iCAD's earnings last quarter?

iCAD, Inc. (NASDAQ:ICAD) issued its quarterly earnings results on Wednesday, April, 28th. The technology company reported ($0.07) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.11) by $0.04. The technology company had revenue of $8.64 million for the quarter, compared to the consensus estimate of $8.13 million. iCAD had a negative net margin of 67.61% and a negative trailing twelve-month return on equity of 55.84%.
View iCAD's earnings history
.

How has iCAD's stock price been impacted by Coronavirus?

iCAD's stock was trading at $11.12 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ICAD shares have increased by 38.4% and is now trading at $15.39.
View which stocks have been most impacted by COVID-19
.

What guidance has iCAD issued on next quarter's earnings?

iCAD updated its first quarter 2021 earnings guidance on Tuesday, May, 4th. The company provided earnings per share guidance of - for the period. The company issued revenue guidance of $8.10 M-, compared to the consensus revenue estimate of $7.89 million.

What price target have analysts set for ICAD?

7 brokerages have issued 12-month target prices for iCAD's stock. Their forecasts range from $19.00 to $27.00. On average, they anticipate iCAD's stock price to reach $23.00 in the next twelve months. This suggests a possible upside of 49.4% from the stock's current price.
View analysts' price targets for iCAD
or view top-rated stocks among Wall Street analysts.

Who are iCAD's key executives?

iCAD's management team includes the following people:
  • Mr. Michael S. Klein, Exec. Chairman & CEO (Age 67, Pay $495.37k)
  • Ms. Stacey M. Stevens, Pres (Age 53, Pay $514.82k)
  • Mr. Jonathan Go, Chief Technology Officer (Age 58, Pay $460.85k)
  • Mr. Charles Ross Carter, Interim Chief Financial Officer (Age 53)
  • Ms. Annette L. Heroux, VP of Admin. (Age 64)
  • Mr. Jeffrey Sirek, Sr. VP & Gen. Mang. of Xoft

What is Michael Klein's approval rating as iCAD's CEO?

4 employees have rated iCAD CEO Michael Klein on Glassdoor.com. Michael Klein has an approval rating of 75% among iCAD's employees.

Who are some of iCAD's key competitors?

What other stocks do shareholders of iCAD own?

Based on aggregate information from My MarketBeat watchlists, some companies that other iCAD investors own include Inseego (INSG), Marvell Technology (MRVL), NVIDIA (NVDA), Aptiv (APTV), JD.com (JD), Advanced Micro Devices (AMD), Bilibili (BILI), Ambarella (AMBA), BioXcel Therapeutics (BTAI) and Telefonaktiebolaget LM Ericsson (publ) (ERIC).

What is iCAD's stock symbol?

iCAD trades on the NASDAQ under the ticker symbol "ICAD."

Who are iCAD's major shareholders?

iCAD's stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (5.61%), Federated Hermes Inc. (2.83%), Parkman Healthcare Partners LLC (2.59%), Pura Vida Investments LLC (1.55%), Geode Capital Management LLC (1.37%) and Russell Investments Group Ltd. (1.05%). Company insiders that own iCAD stock include Andy Sassine, R Scott Areglado and Stacey M Stevens.
View institutional ownership trends for iCAD
.

Which institutional investors are selling iCAD stock?

ICAD stock was sold by a variety of institutional investors in the last quarter, including Granite Point Capital Management L.P., Sturgeon Ventures LLP, BlackRock Inc., Renaissance Technologies LLC, Northern Trust Corp, UBS Group AG, White Pine Capital LLC, and Nuveen Asset Management LLC. Company insiders that have sold iCAD company stock in the last year include Andy Sassine, R Scott Areglado, and Stacey M Stevens.
View insider buying and selling activity for iCAD
or view top insider-selling stocks.

Which institutional investors are buying iCAD stock?

ICAD stock was purchased by a variety of institutional investors in the last quarter, including Pura Vida Investments LLC, Calamos Advisors LLC, Flagship Harbor Advisors LLC, Parkman Healthcare Partners LLC, Goldman Sachs Group Inc., Federated Hermes Inc., Schonfeld Strategic Advisors LLC, and Manatuck Hill Partners LLC.
View insider buying and selling activity for iCAD
or or view top insider-buying stocks.

How do I buy shares of iCAD?

Shares of ICAD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is iCAD's stock price today?

One share of ICAD stock can currently be purchased for approximately $15.39.

How much money does iCAD make?

iCAD has a market capitalization of $384.49 million and generates $31.34 million in revenue each year. The technology company earns $-13,550,000.00 in net income (profit) each year or ($0.37) on an earnings per share basis.

How many employees does iCAD have?

iCAD employs 113 workers across the globe.

What is iCAD's official website?

The official website for iCAD is www.icadmed.com.

Where are iCAD's headquarters?

iCAD is headquartered at 98 SPIT BROOK ROAD SUITE 100, NASHUA NH, 03062.

How can I contact iCAD?

iCAD's mailing address is 98 SPIT BROOK ROAD SUITE 100, NASHUA NH, 03062. The technology company can be reached via phone at 603-882-5200 or via email at [email protected]


This page was last updated on 5/18/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.